Journal articles on the topic 'Truss purlin'

The snow load of a space truss structure subjecting is unevenly distributed after snowstorm disaster, which caused uneven forcing and local damage of the members and roof purlin of the original space truss. The damaged members and roof purlins were strengthened and replaced in loaded condition in order to guarantee the space grid structural safety. The results during the construction process have shown that the presented strengthening plan is successful, which can provide us a good reference of the similar projection.

The paper analyses the influence of the rotational flexibility of beam-column connection on the roof plane rigidity of the longitudinally braced frame-purlin cover of the solid wall hall. The cover is adapted to obtain thermal energy from solar radiation. The roof cover is then provided in the form of a transparent glass barrier which requires considerable roof plane rigidity. The analysis aimed to compare the roof plane rigidity of the frame-purlin cover to those of space structures and truss-purlin covers, depending on the type of longitudinal bracing and rotational rigidity of the beam-column connection. The investigations were conducted for three types of roof plane bracing and different rigidity indexes of the beam-column connection (from u=0 – pin connection, through u=0.25; 0.5; 0.75 – semi-rigid connection, to u=1 – rigid connection). In the transfer of horizontal forces, the interaction of the rigidity of frames with flexible nodes (beam-column) with longitudinal roof plane bracings supported by lateral bracings of gable walls was observed. The highest roof plane rigidity was demonstrated by 2X-shaped and K-shaped braces with rigid nodes at frame corners.

The roof of the so called ‘Pilgrims’ Hall’, Winchester, now dated to c. 1308, has long been recognized as one of the earliest surviving examples of hammerbeam construction. It is somewhat surprising, therefore, that the complete medieval structure, of which the Pilgrims’ Hall forms rather less than half, has not previously been investigated in detail. In its original form it was a six bay building covered by a single roof, which, though of one constructional phase, employed a variety of principal truss types (fig. 1). The three bays at the north end of the complex have masonry walls: they comprise the actual Pilgrims’ Hall, whose most impressive feature is its pair of hammerbeam trusses (pl. XLa). The other three bays had timber framed walls, and were subdivided into a second, two bay hall with a central base cruck truss, and a single bay at the south end of the building. In this paper the term ‘Pilgrims’ Hall’ is used to denote only the three bay hammerbeam hall, while the entire original structure is referred to as the ‘Pilgrims’ range’.The roof and timber framing of the complex must surely rank with those few structures that, in the words of the late R. T. Mason, ‘stand out for their contribution to overall knowledge’. The outstanding significance of the Pilgrims' range in the study of early medieval carpentry is that it included four major ‘aisle-derivative’ roof truss types in a single building: a true aisled truss, a base cruck truss, two hammerbeam trusses, and at least one raised aisle truss. The existence of continuous longitudinal members (arcade plates, cornice plates and a central purlin) and the uniform upper roof structure throughout the length of the range show that the entire roof was erected in a single campaign.

Concrete beam and slab system is commonly applied in the main plant roof of hydropower station, which is difficult for construction and slow, having a great impact on the construction period. For the main plant roof structure (span of 30 metres)of GuanDi hydropower station in Yalong River, this paper proposes three light steel roof systems, which are arched corrugated steel roof, light gauge-steel and shell roof, and carries detailed analyses and comparisons on the force calculation, appearance, the amount of steel, site construction, anticorrosive performance and other aspects. Regarded that the light gauge-steel roof is the most suitable system for the main plant roof of hydropower station, this paper introduces the layout, arched truss design and purlin of light gauge-steel roof, providing reference for design and application of similar projects.

Pekembangan teknologi informasi dibidang konstruksi berkembang semakin pesat. Teknologi virtual building dengan sistem komputasi dikembangkan dengan prinsip Building Information Modeling (BIM), mampu menciptakan modeling secara 3D di bidang konstruksi (arsitektur, struktur dan MEP). Tekla Structures salah satu perangkat lunak berbasis BIM yang mampu membuat dan mengelola data akurat dan rinci. Tekla Structures mempunyai kemampuan dalam modeling, detailing, engineering, drawing, reporting, scheduling. Pembangunan atap dome baja menggunakan sistem truss pada Gedung Olahraga UTP Surakarta dengan bentang 40meter. Memerlukan detail drawing yang baik pada proses fabrikasi, sehingga didapatkan hasil yang presisi pada saat pemasangan. Proses pemasangan dilakukan secara segmented. Gambar fabrikasi atap dome terdiri dari Gambar Arrangement, Section drawing : Kuda-kuda K1 & K2, Anchor bolt plan, Lateral & Windbrace, Purlin & Sagrod, Detail drawing : Rafter 1 s/d 13, Cutting plan. Dan report bill of materials (BOM) terdiri dari Assembly List, Assembly Part List, Bolt List, Material List dan Part List.

The EN 1993-1-1 model of equivalent stabilizing force qd and Rd of bracings conservatively assumes that the braced member is compressed with a force constant along its length. This assumption is incorrect since the axial force distribution varies along the length of the braced member. As a result, the braced member generates equivalent stabilizing forces different from equivalent force qd and Rd acc. to EN 1993-1-1. This paper presents parametric studies of the equivalent stabilizing forces of the braced, compression top chord of roof trusses. The girder’s top chord is compressed parabolically by a variable axial force. The values of the axial compressive forces is: Nsupp in the support zone of truss and Nspan in the central zone of truss. Parametric analyses of the equivalent stabilizing force and the stress of the purlins and the bracings depending on axial forces Nsupp and Nspan in the braced member were carried out. The investigated problem is illustrated with exemplary calculations of the equivalent force in trusses.

Question 1: Who are the moderate Muslims, and what are their beliefs andpolitics?FAR: The debate among the participants shows that while the term moderateMuslim is problematic, there is a need to define the attitudinal differencebetween Muslims who can be worked with from those who cannot. Isuggest that the defining feature is between those who believe in a pluralist,multicultural, multi-religious societal contract that allows for differencesof opinions within an over-arching construct, as opposed to thosewho believe in a societal contract that has no space for other religions, ethnicities,or cultures, or even intra-Islamic differences of opinion.1The latter attitude leads to the phenomenon known as “Islamist terrorism,”the modern-day version of the seventh-century Kharijites, who foughtand ultimately assassinated Ali, Prophet Muhammad’s son-in-law, and who,over the following century, developed a political philosophy that justifiedmurdering fellow Muslims, including innocent women and children.Contemporary Muslims need to support that aspect of the war on terror thatis a true jihad against all forms of terrorism, known in classical Islamicjurisprudence as hirabah, and anarchic terrorism that tears the social fabricessential to well-functioning societies. But this cannot be done withoutsimultaneously purging Muslim societies of some other modern “isms” thathave “terrorized” Muslims and still continue to deny them their inalienablehuman rights under the Shari`ah ...

Abstract One of the major advantages of light gauge steel structures made of cold-formed steel sections is their low weight so the production of typical single-storey steel structures of this kind of profiles is still rising. The well known profiles, e.o. Z-sections, C-sections and the so called hat-sections studied and described in the literature, are used mainly as purlins or truss components. A new profile GEB was patented for the use for primary load-bearing member in fabricated steel frames. According to the code [1] every novel cross section should be tested to assign the deformation shape and bearing capacity. The paper deals with the numerical and experimental research of bearing capacity of cold formed GEB profiles. The deformation shape and limit load was obtained from bending tests. The GEB cross section bearing capacity was also determined according to codes [1, 2].

SUMMARYThe asexual stages ofPlasmodiumliving within the erythrocyte result in growth-related changes in the permeability properties of the red cell for substances such as glucose, amino acids, purine nucleosides, sodium, potassium, calcium, zinc, iron and several antimalarial drugs such as chloroquine, amodiaquine and mefloquine. In most cases such changes do not appear to be due to a modification in the affinity or specificity of red cell transporters; indeed, for most substances the membrane-associated transporters are either unaffected or are partially inactivated. In malaria-infected erythrocytes, where a striking increase in influx has been observed, it has been attributed to the insertion of parasite-encoded transporters into the red cell membrane or the formation of aqueous leaks and/or pores. Leak formation, in the vast majority of cases, does not appear to be dependent on the insertion of plasmodial proteins into the red cell membrane. However, since the data presently available are less than satisfactory for discriminating amongst the various possible transport mechanisms future studies will require painstaking efforts and carefully controlled conditions to discriminate amongst the various transport systems which are operational in the malaria-infected red cell and the parasite.

Much recent work in the study of public administration has emphasized new challenges and relatively unusual aspects of management. However, it is likely that the core features of traditional public administration play a crucial role, particularly regarding the delivery of performance. The most venerable of these aspects of public management have to do with “internal” management. We focus here on a cluster of key, intertwined management practices: setting challenging but feasible goals, building trust through credible commitments, encouraging employee participation, and providing feedback. We examine the relationship between such internal management at the mid-level, as perceived by subordinates rather than the managers themselves, and educational performance for more than 1,100 schools in the New York City school system over a 3-year period. The results indicate that internal management matters, often sizably, for delivering educational outcomes. The findings are robust to autoregressive specifications and the purging of halo effects, and they hold across multiple performance measures. Managers’ setting challenging goals appears to be especially important in generating educational results.

Представлено конструктивно-компоновочное решение стержней Y-образных и Ψ-образных очертаний в фермах с ромбической решеткой или фермах с ромбической решеткой и полустойками (полуподвесками), техническая новизна которого подтверждена результатами патентной экспертизы. Универсальность этого решения для ферменных конструкций обеспечивает ту эффективность, с какой оно применимо к грузовым верхним поясам, грузовым нижним поясам или грузовым верхним и нижним поясам одной и той же решетки. Повышена степень унификации фермы из прямоугольных гнутосварных профилей (профильных труб) за счет использования в верхнем поясе форм и наружных габаритов поперечных сечений, принятых для нижнего пояса. При этом ресурсы несущей способности разнятся между ними в пределах однопроцентного порога, что обеспечивает необходимую и достаточную равнопрочность обоих поясов для их более рациональной унификации. Узловые соединения стержней разных очертаний с верхними поясами позволяют оптимизировать опорные условия настилов и прогонов с уменьшением размеров их грузовых площадей. Возрастание общего количества прогонов приводит к снижению их суммарной массы и массы кровельного ограждения, что весьма актуально для вариантного и оптимального проектирования строительных конструкций с учетом риска лавинообразного обрушения. Выявлена перспективность применения нового технического решения в составе несущих и связевых систем различных зданий и сооружений. The structural and layout solution of rods of Y-shaped and Ψ-shaped outlines in trusses with a rhombic lattice or trusses with a rhombic lattice and half-posts (half-suspensions) is presented, the technical novelty of which is confirmed by the results of patent examination. The versatility of this truss solution is as effective as it is for load tops, load bottoms, or load tops and bottoms of the same grid. The degree of unification of the truss of rectangular bent-welded profiles (shaped pipes) has been increased due to the use in the upper chord of the forms and outer dimensions of the cross-sections adopted for the lower chord. At the same time, the resources of the bearing capacity differ between them within a one- percent threshold, which ensures the necessary and sufficient equal strength of both belts for their more rational unification. Nodal connections of rods of different shapes with the upper chords allow to optimize the support conditions of decks and purlins with a decrease in the size of their cargo areas. An increase in the total number of runs leads to a decrease in their total mass and the mass of the roofing, which is very important for the variant and optimal design of building structures, taking into account the risk of an avalanche collapse. The prospect of using a new technical solution in the composition of bearing and communication systems of various buildings and structures has been revealed.

Abstract Objectives Significance and objectives of this study is to (1) investigate influences of curricular intervention on student lifestyle choices using self reporting assessment tools including CCAPS instrument and (2) determine if a correlation exist between curricular intervention and an increase in healthy self reported evaluations and outcomes. Methods A Health Behavior Study was conducted by Healthy Campus 2020® a campus-wide comprehensive wellness intervention program. IRB approved health behavior surveys were disseminated to students (N = 645) investigating (co-) curricular intervention to assist with increasing health awareness among students. Counselors evaluated students (N = 101) using Counseling Center Assessment of Psychological Symptoms (CCAPS) a high-quality multi-dimensional assessment tool with distinct subscales related to psychological and distress symptoms. Among the 8 subscales measured, responses to eating concerns were highlighted. Correlation between mental wellness and nutrition were observed. Coded responses were obtained and analyzed. Results Descriptive analytics and correlation coefficient are used to analyze data responses. Students enrolled in courses embedded with 8 STANDOUT® health principles (sunlight, temperance, rest, nutrition, water, outdoors, physical activity and trust) increased in the number of positive health behavior responses after one month. Responding to healthy # of steps an increase of 78% students indicated “yes” compared to one month prior and 90% of students achieved 2500 + steps/day. An 11% increase of students reported consuming healthier diets including recommended daily intake of fruits, vegetables and whole grains. CCAPS-62 results showed 44.5% of students reported positive responses to body image. A high % of students reported they do not engage in eating disorders including purging (92%) or refrain from eating (93.1%) to control their weight or feel better about themselves, respectively. Conclusions (Co-) Curricular intervention may have the ability to increase health awareness and produce healthier outcomes among university students. CCAPS can be used to assess students experiencing forms of depression or anxiety that may negatively impact their academic success. Funding Sources Funding for research conducted through HC2020® was provided by The Dept of Education Title III.

Purpose This paper stems from a 12-month collaborative enquiry between a group of Syrian academics in exile in Turkey and academics from the University of Cambridge into the state of Syrian Higher Education after the onset of the conflict in 2011. The purpose of this paper is to draw on 19 open-ended interviews with exiled Syrian academics; two focus groups; mapping and timeline exercises; and 117 interviews collected remotely by collaborating Syrian academics with former colleagues and students who were still living inside Syria at the time of data collection. The findings of the research suggest that Syrian HE after 2011 was fragmented across regions; in some cases non-existent, and in others deemed to be in a state of reform in order to meet student needs. Key issues that emerged from this work are human rights’ abuses directed against academics and students including the detainment, purging and kidnapping of academics, an increased militarisation of university life and a substantive loss of academic and human capital. Design/methodology/approach The overall design involved two workshops held in Turkey (in June and July, 2017) at which the Cambridge team explained the stages of undertaking qualitative research and planned the collaborative enquiry with Syrian co-researchers. The first workshop addressed the nature of qualitative research and explored the proposed methods of interviewing, using timelines and mapping. The instruments for interviewing were constructed in groups together and mapping was undertaken with the 21 Syrian academics in exile who attended the workshop. Syrian academics also built their own research plans as a way of expanding the consultation dimension of this project inside Syria, engaged in survey and interview protocol planning and discussed ways to access needed documentation which could be drawn upon to enrich the project. The Syrian co-researchers interviewed remotely HE staff and students who had remained in, or recently left, Syria; the key criterion for group or participant selection was that they had recent and relevant experience of Syrian HE. The second workshop focused on data analysis and writing up. There was also wide consultation with participants inside and outside Syria. As part of the research, the Cambridge team conducted open-ended interviews with 19 Syrian academics and students living in exile in Turkey. This involved interviewing Syrian scholars about their experiences of HE, policy changes over time and their experiences of displacement. The researchers developed this protocol prior to the capacity-building workshops based on previous research experience on academic and student displacement, alongside extensive preparation on the conditions of Syrian HE, conflict and displacement. In addition to interviewing, a pivotal element of methodological rigour was that the authors sought to member check what participants were learning through mapping and timeline exercises and extensive note-taking throughout both workshops. The major issues that the authors confronted were ethical concerns around confidentiality, the need to ensure rigourously the protection of all participants’ anonymity and to be extremely mindful of the political sensitivity of issues when interviewing participants who may not feel able to fully trust “outsider” researchers. Issues of social trust have been reported in the literature as one of the most significant drawbacks in conducting research in “conflict environments” (see Cohen and Arieli, 2011) where academics and students have been working and/or studying in autocratic regimes or were operating within political contexts where being open or critical of any form of institutional life such as university work or the nation could cost them their jobs or their lives. Findings The accounts of Syrian academics and students emerging from this work point to some of the state-building expressions of HE manifested in the shaping of professional and personal experiences, the condition and status of HE, its spatial arrangements and their associated power formations, and resulting in feelings of intense personal and professional insecurity among Syrian scholars and students since 2011. While acknowledging that the Syrian situation is deemed one of the worst humanitarian crises in the region in recent decades, these accounts resonate, if in different ways, with other studies of academics and students who have experienced highly centralised and autocratic states and tightly regulated HE governance regimes (Barakat and Milton, 2015; Mazawi, 2011). Originality/value Currently, there is virtually no research on the status and conditions of higher education in Syria as a consequence of the war, which commenced in 2011. This work presents a first-person perspective from Syrian academics and students on the state of HE since the onset of the conflict. The major contribution of this work is the identification of key factors shaping conflict and division in HE, alongside the political economies of HE destruction which are unique to the Syrian war and longstanding forms of authoritarian state governance.

Background: Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a rare disorder caused by ADA gene mutations, leading to lymphotoxic build-up of purine metabolites and profound immunodeficiency. Historically, enzyme replacement therapy (ERT) has been used as a bridge therapy until patients can receive an allogeneic hematopoietic stem cell transplantation (HSCT), ideally from a matched related donor (MRD) or, if none is identified, a non-matched and/or unrelated donor. We developed a self-inactivating lentiviral vector (LV), denoted EFS-ADA LV, encoding the human ADA cDNA sequence under the control of a shortened human elongation factor 1α gene promoter. A fresh or cryopreserved formulation of a drug product (OTL-101), composed of autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with EFS-ADA LV, was evaluated in 2 prospective, non-randomized Phase I/II clinical trials at 2 USA centers. We report on safety and efficacy of OTL-101 in 30 ADA-SCID pediatric gene therapy (GT) subjects treated from 2013-2017 with a median follow up (FU) of 24 months (mo; range 12-26 mo), compared to a historical cohort of 26 ADA-SCID patients treated with HSCT. Methods: UCLA Fresh Study (NCT01852071): Autologous CD34+ HSPCs were isolated from bone marrow and pre-stimulated with cytokines before transduction with EFS-ADA LV to yield OTL-101, which was infused as a fresh formulation in 20 subjects (9 male, 11 female; aged 4 mo-4.3 yrs). Single dose busulfan (4 mg/kg) was administered prior to infusion of OTL-101. Subjects were followed for 24 mo. UCLA Cryo Study (NCT02999984): 10 subjects (4 male, 6 female; aged 5-15 mo) received a cryopreserved formulation of OTL-101, which allowed for an extended shelf-life and full quality control prior to infusion. Busulfan was administered in 2 doses, the first at 3 mg/kg and the second adjusted to target a total area under the curve of 4,900 µM*min (20 ng/mL*hr). At the time of analysis, all subjects reached 12 mo FU (except 1 subject who was withdrawn from the study due to lack of engraftment); 7 subjects reached 18 mo of FU. Historical Control Group: 26 patients (aged 0.2 mo-9.8 yrs) were treated with allogeneic HSCT (MRDs n=12, non-MRDs n=14) at Great Ormond Street Hospital, UK (n=16) or Duke University Children's Hospital, USA (n=10) from 2000-2016. Results: Sustained engraftment of genetically modified HSPCs was observed in 29/30 GT subjects by 6-8 mo and persisted through FU in both studies, based on vector gene marking in granulocytes and CD3+ T cell reconstitution (Figure). Subjects who engrafted maintained long-term metabolic detoxification from deoxyadenosine nucleotides after stopping ERT approximately 1 mo post-GT. At last FU (median 24 mo; range 12-24 mo) in the GT group, overall survival (OS) was 30/30 (100%) and event-free survival (survival in the absence of ERT reinstitution or rescue allogeneic HSCT; EvFS) was 29/30 (97%). OS and EvFS were higher in the GT group at last FU compared with HSCT controls (with or without an MRD) at 2 years (Table). One of 30 OTL-101 subjects (3%) did not engraft and was restarted on ERT; the subject was withdrawn from the study at 5.9 mo and subsequently received a rescue HSCT, whereas 42% of HSCT patients required rescue HSCT, PEG-ADA ERT or died. Among the 20 OTL-101 subjects in the UCLA Fresh Study who reached 2 years FU, 18 (90%) stopped immunoglobin replacement therapy (IgRT), compared to 52% of HSCT patients. Preliminary results were observed in 5/7 (71%) OTL-101 subjects in the UCLA Cryo Study with more limited (18 mo) FU. Twelve OTL-101 subjects experienced one or more serious adverse events, most frequently infections and gastrointestinal events; only 1 of which was considered treatment-related (bacteremia due to product contamination). In the GT group, there were no events of autoimmunity with ≤24 mo FU. Due to the autologous nature of OTL-101, there was no incidence of graft vs host disease (GvHD); in contrast, 8 HSCT patients experienced GvHD events (5 acute, 3 chronic events), 1 of which resulted in death. Conclusions: Based on sustained gene correction and restoration of immune function in all subjects who engrafted, treatment of ADA-SCID with OTL-101 has a favorable benefit-risk profile. Key correlates of engraftment were consistent across the expanded cohort. Importantly, higher rates of OS and EvFS compared with HSCT (with or without an MRD) were observed. Disclosures Kohn: Orchard Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Inventor on IP licensed from UC Regents to Orchard Therapeutics. Future royalties may occur., Research Funding; NIH: Research Funding. Shaw:Orchard Therapeutics: Consultancy, Other: Personal fees and non-financial support; NIH: Research Funding. Carbonaro-Sarracino:NIH: Other: Salary while working on project at UCLA 2013-2016, Research Funding; Orchard Therapeutics: Consultancy, Employment. De Oliveira:National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London: Research Funding; CIRM: Research Funding; National Gene Vector Repository: Research Funding; NIAID, NHI: Research Funding; Medical Research Council: Research Funding. Terrazas:California Institute for Regenerative Medicine: Research Funding; Gene Therapy Resource Program, NHLBI/NIH: Research Funding. Hollis:Curative Therapeutics: Consultancy, Other: Personal fees. Trevisan:Orchard Therapeutics: Research Funding. Arduini:Orchard Therapeutics: Employment, Equity Ownership. Lynn:Orchard Therapeutics: Employment, Equity Ownership. Kudari:Orchard Therapeutics: Employment, Equity Ownership. Spezzi:Orchard Therapeutics: Employment, Equity Ownership. Buckley:Duke University: Research Funding. Booth:SOBI: Consultancy; GSK: Honoraria; NovImmune: Consultancy. Thrasher:Generation Bio: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Orchard Therapeutics: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees; 4BIOCapital: Membership on an entity's Board of Directors or advisory committees; Rocket Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Gaspar:Orchard Therapeutics: Employment, Equity Ownership, Patents & Royalties: Lentiviral vector for gene therapy of ADA-SCID.

Moxetumomab pasudotox-tdfk is a first-in-class recombinant CD22-directed cytotoxin approved in the US for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL). The pivotal, multicenter, open-label, single-arm trial (Study 1053; NCT01829711) evaluated the efficacy, safety, immunogenicity, and pharmacokinetics of moxetumomab pasudotox-tdfk monotherapy in patients with relapsed/refractory HCL. Here we present the final analysis, describing the long-term follow-up of patients in Study 1053, with a median follow-up of 24.6 months (range 1.2-71.7). Eligible patients had received ≥ 2 prior systemic therapies, including ≥ 2 courses of a purine nucleoside analog (PNA) or 1 course of a PNA followed by ≥ 1 course of rituximab or a BRAF inhibitor. Patients received moxetumomab pasudotox-tdfk 40 µg/kg intravenously on days 1, 3, and 5 of each 28-day cycle for 6 cycles, or until minimal residual disease (MRD)-negative complete response (CR), disease progression, initiation of alternate therapy, or unacceptable toxicity. Disease response and immunohistochemistry MRD status were determined by blinded independent central review. The primary endpoint was durable CR (achieving CR and maintaining hematologic remission [HR] for > 180 days). Durable CR with HR ≥ 360 days was measured in this final analysis. HR was defined as hemoglobin ≥ 11.0 g/dL, absolute neutrophil count ≥ 1.5 × 103/µL, and platelet count ≥ 100 × 103/µL without receiving transfusions or growth factors within the 4 preceding weeks of assessment. Eighty patients (63 males; median age 60 years [range 34-84]) were enrolled and treated with moxetumomab pasudotox-tdfk. The median number of prior systemic therapies was 3 (range 2-11); 48.8% of patients were PNA-refractory and 37.5% were unfit for PNA retreatment. The median number of treatment cycles administered was 6 (range 1-7). The durable CR rate was 36.3% (29/80 patients; 95% confidence interval [CI]: 25.8-47.8%), durable CR rate with HR ≥ 360 days was 32.5% (26/80 patients; 95% CI: 22.4-43.9%), and the overall CR rate was 41.3% (33/80 patients; 95% CI: 30.4-52.8%) (Table). Overall, 27/33 (81.6%) patients who achieved a CR also achieved MRD-negative status (33.8% of all patients). HR was achieved by 64/80 patients (80.0%). The median duration of HR from CR was 62.8 months (Figure) and median progression-free survival was 41.5 months (range 0.0+ to 71.7). Per the primary analysis, the most frequent treatment-related adverse events (AEs) were nausea (28%), peripheral edema (26%), headache (21%), and pyrexia (20%). Treatment-related Grade 3/4 AEs were reported in 24 patients (30.0%) and serious AEs in 28 (35.0%). Treatment-related AEs led to study drug discontinuation in 8 patients (10.0%): hemolytic uremic syndrome (HUS), n = 4 (5.0%); capillary leak syndrome (CLS), n = 2 (2.5%); and increased blood creatinine, n = 2 (2.5%). Grade ≥ 3 CLS events occurred in 2 patients (2.5%) and Grade ≥ 3 HUS occurred in 5 patients (6.3%). In general, CLS and HUS events were manageable and reversible with appropriate supportive care and monitoring. Based on primary and follow-up analyses of serum creatinine, there was no decline in renal function over time; 12 months post-treatment all mean (SD) serum creatinine laboratory values stayed within normal limits, which suggests current management strategies for HUS (oral hydration, i.v. fluid supplementation on the day of infusion, and the use of dexamethasone) are adequate. With 24.6 months of follow-up, 4 deaths were reported: 2 due to study disease progression and 2 due to an AE (1 each of pneumonia and septic shock). Moxetumomab pasudotox-tdfk treatment was associated with a manageable safety profile. Moxetumomab pasudotox-tdfk achieved a high rate of durable responses, demonstrating the ability to achieve MRD negativity in heavily pretreated patients with HCL. Disclosures Kreitman: Genentech: Research Funding. Dearden:Abbvie: Honoraria; Genentech: Honoraria; Janssen: Honoraria; Sanofi: Honoraria. Zinzani:MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; VERASTEM: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CELLTRION: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GILEAD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; JANSSEN-CILAG: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; IMMUNE DESIGN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSAPHARMA: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ROCHE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SERVIER: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SANDOZ: Membership on an entity's Board of Directors or advisory committees; KYOWA KIRIN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CELGENE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SANOFI: Consultancy; PORTOLA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Robak:Amgen: Consultancy, Other: Travel grant; UCB: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Other: Travel grant, Research Funding; Roche: Consultancy, Other: Travel grant, Research Funding; Abbvie: Consultancy, Honoraria, Other: Travel grant, Research Funding; Gilead: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Acerta: Research Funding; Morphosys AG: Research Funding; Takeda: Consultancy, Research Funding. le Coutre:Novartis: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau. Gjertsen:Research Council of Norway: Research Funding; Daiichi Sankyo: Consultancy; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; BerGenBio: Consultancy; KinN Therapeutics AS: Equity Ownership; Seattle Genetics: Consultancy; ERA PerMed: Research Funding; Haukeland University Hospital / University of Bergen: Employment; ACTII AS: Equity Ownership; Astellas: Consultancy; BerGenBio AS: Membership on an entity's Board of Directors or advisory committees; The Norwegian Cancer Society: Research Funding; Helse Vest Health Trust: Research Funding; EU Horizon 2020: Research Funding. Troussard:Innate Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Other: Research Support; Sysmex: Other: Research Support. Roboz:Argenx: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Actinium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amphivena: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astex: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celltrion: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Eisai: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Orsenix: Consultancy, Membership on an entity's Board of Directors or advisory committees; Otsuka: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trovagene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Karlin:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; AMGEN: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support. Kuptsova-Clarkson:AstraZeneca: Employment, Equity Ownership. Liu:Acerta Pharma: Employment. Patel:Acerta Pharma: Employment, Equity Ownership; AstraZeneca: Equity Ownership.

Abstract Background Almost all national/international OP management guidelines emphasise the importance of ruling out ‘secondary markers’ of OP, that is, biochemical, haematological, serological and hormonal blood anomalies that might indicate underlying undetected diagnoses that might contribute to bone loss and/or fracture risk. Moreover, these assessments may identify sub-optimally controlled established diagnoses. Identifying vertebral fragility fractures (VFFs) at baseline/initial review is scarcely undertaken despite numerous studies that indicate the predictive capacity of the high risk of fractures at any site conferred by the presence of moderate-to-severe VFFs. There is little in the literature on rates of 'secondary marker' anomalies and VFFs at initial review appointments in OP clinics, the data of which is essential to understand when developing OP services and management pathways. We assessed the rates of blood test abnormalities and VFFs in OP patients seen at the bone health clinic, Croydon Health Services NHS Trust. Methods We conducted a retrospective review of OP patients seen between February-June 2018 at Purley Memorial Hospital. We assessed the results of secondary markers of OP blood tests: FBC, U&Es, LFTs, ESR, CRP, TFTs, HbA1c/fasting glucose, immunoglobulins, electrophoresis, coeliac antibodies, vitamin-D, calcium, phosphate, alkaline phosphatase, PTH, vitamin-B12, folate and ferritin and when required testosterone, FSH, LH, magnesium, cortisol, urinary calcium and urinary paraproteins. We also reviewed for the presence of moderate-to-severe VFFs using thoracolumbar spine X-rays (Ghent classification). Results 201 patients were included. Mean age was 70 years (range:37-96), with approximately 9:1 female:male ratio. 45% (90/201) had blood test abnormalities on secondary marker testing identifying new diagnoses: 5% had coeliac antibodies, 3% hypercalcaemia & hyperparathyroidism, 3% hypothyroidism, 2% haematological disorders (3 MGUS and 1 myeloma), 30% (6/21 male cohort) had testosterone deficiency, 20% vitamin-D deficiency, 12% had either vitamin-B12, folate or ferritin deficiency. Of the 18% with pre-existing thyroid-disorders, a third of these patients were not euthyroid. 30% (29/90) of patients with blood abnormalities had multiple anomalous results. In total, 48% (96/201) patients were identified with moderate-to-severe VFFs; 71% (68/96) of these had either more VFFs than previously known by the patient/referrer (35%) or -the majority- had newly identified VFFs (65%). Conclusion Just under half-of-subjects had blood test anomalies indicating previously unknown diagnoses that could lead to bone loss and increased fracture risk if left unaddressed. Almost 1/3 of these had multiple abnormalities increasing their risk even further. The commonest diagnoses included endocrinopathies (especially hypothyroidism), vitamin deficiencies (especially vitamin D), coeliac disease and haematological disorders. Given the incidences of these issues, it is essential that OP services undertake thorough 'secondary marker' investigations to identify and improve the overall management of OP patients. Furthermore, there was a high rate of VFFs (48%) with almost half of these patients being newly identified at the clinic and 25% having had more VFFs than previously known. Therefore, 1/3 of the whole cohort had previously unknown moderate-to-severe VFFs. This clearly indicates that VFFs are being underdiagnosed in OP patients despite the important prognostic and predictive value that the presence of VFFs confer when assessing patients' fracture risk. Disclosures R. Rajak Honoraria; Speaker fees from Roche, Eli Lilly, Amgen, Internis. Chair fees Roche, Eli Lilly, Norvartis, Abbvie, UCB. S. Mahendrakar None. A. Perren None. M. Zaman None.